DexCom Stock Declines Following Strong Preliminary Q4 Results
DexComDexCom(US:DXCM) ZACKS·2026-01-16 18:45

Core Insights - DexCom, Inc. (DXCM) reported strong preliminary results for Q4 and full-year 2025, with shares declining nearly 2.5% post-announcement [2][11] Q4 2025 Preliminary Results - Total revenues for Q4 2025 reached approximately $1.26 billion, marking a 13% increase from Q4 2024, exceeding the Zacks Consensus Estimate of $1.25 billion [3][11] - U.S. revenues were about $892 million, reflecting an 11% year-over-year growth, while international revenues increased by 18% to around $368 million [3][11] Full-Year 2025 Preliminary Results - Total revenues for the full year are estimated at $4.66 billion, a 16% increase from 2024, surpassing the Zacks Consensus Estimate of $4.64 billion [4][11] - Adjusted gross profit margin is estimated at approximately 61%, with adjusted operating margin projected between 20-21% for the full year [5] Margin and Operational Insights - The company faced challenges in Q3 due to elevated manufacturing scrap rates and higher freight costs, but operational expense leverage helped achieve overall margin expansion [5] - DexCom anticipates a return to normalized margin levels supported by improvements in manufacturing and the rollout of higher-margin products like the G7 15-day system [6] 2026 Outlook - For 2026, DexCom projects total revenues between $5.16 billion and $5.25 billion, indicating an estimated growth of 11-13% over 2025 [7] - The company expects adjusted gross profit margins to improve to 63-64% and adjusted operating margins to approximately 22-23% [7] Market Position and Growth Drivers - The positive outlook is supported by expected sensor volume growth, increased continuous glucose monitoring (CGM) adoption, and ongoing international market expansion [8][9] - DexCom is closing 2025 with strong performance, having launched the G7 15-day system and maintaining a leadership position in the CGM market [9] Stock Performance - Over the past three months, DexCom's shares have gained 3.6%, compared to a 6.3% rise in the industry and a 5.2% gain in the S&P 500 [10]

DexCom Stock Declines Following Strong Preliminary Q4 Results - Reportify